Skip to main content
OpenTrials
Completed

NCT Number: NCT06137456

First Report of a New Exoskeleton in Incomplete Spinal Cord Injury

The goal of this clinical trial is to compare the effects of exoskeletal robotic therapy and conventional exercise therapy in incomplete spinal cord injury (SCI). The main questions it aims to answer are:

* Is exoskeletal robotic therapy effective in improving functional ambulation in SCI? * Is exoskeletal robotic therapy effective in enhancing Activities of Daily Living in SCI?

Participants treated with either:

* Exoskeletal robotic therapy along with conventional exercise therapy, or * Only conventional exercise therapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ankara City Hospital

Ankara, 06800, Turkey (Türkiye)

About this study

Background: Intensive walking practice is a task that requires performance above the limits of conventional therapy. As a solution, robot-assisted exoskeletons that allow walking on the ground are produced. The exoskeletons can allow the user to perform intense, targeted, and multi-repetitive movements and at the same time provide stability and balance during walking. In this study, a new robot-supported exoskeleton system was used for gait and balance rehabilitation. This study is important as the first clinical study of a new walking system. The primary aim of the study was to evaluate the effect of the FreeGait® exoskeleton system (BAMA Technology, Ankara, Türkiye) on gait parameters in patients with motor incomplete spinal cord injury. The secondary aim was to assess its impact on quality of life and independence.

Methods: Fourteen participants with incomplete spinal cord injury were included in the study. An average of 20.7 sessions of exoskeleton therapy was administered to the study group. Gait training was attempted to be diversified as much as possible during the exoskeleton training. 10MWT, Timed Up and Go Test (TUG), WISCI II, Berg Balance Scale (BBS), Visual Analogue Scale (VAS) for fear of falling, Spinal Cord Independence Measure (SCIM III), World Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF) were used for evaluation.

Results: WISCI II levels improved significantly in the study group (p = 0.031). Overground walking speed means calculated from 10MWT increased by 66%, twofold compared to the control group (p = 0.016, p = 0.063, respectively). The mobility subscale of SCIM III, the total SCIM III scores, and the WHOQOL-BREF physical health domain score increased significantly, contrary to the control group (p < 0.05). However, there was no difference in the mean change of all measurements between groups (p > 0.05).

Conclusions: Gait training with the new exoskeleton system contributes to functional walking skills. It is possible that the residual motor learning ability, together with the balance and compensation mechanisms, played a role in the outcome. It is also important that this improvement in functional mobility is reflected in ADLs. It can be supposed that walking in different patterns, and speeds gives a way to simulate daily living conditions, which is the basis of the achievements in this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • SCI below T4,
  • Patients with AIS (American Spinal Injury Association Impairment Scale) C or D injury,
  • Bilateral quadriceps femoris manual test scores ≥ 2,
  • Upper extremity manual muscle test scores = 5,
  • Participants with adequate spinal stabilization

Exclusion criteria

  • Severe spasticity (Modified Ashworth Scale ≥ 3),
  • Difference in leg length,
  • Pregnancy, osteoporosis,
  • Contracture, or limited range of motion

Treatment and study plan

Exoskeletal robotic therapy for walking.

Device

Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.

Conventional exercise therapy

Other

Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.

Primary outcomes

  1. Walking Index in Spinal Cord Injury II

    Time frame: 23 months

    Walking Index in Spinal Cord Injury II for walking independence level assessment

Secondary outcomes

  1. Ten-Meter Walking Test

    Time frame: 23 months

    Ten-Meter Walking Test for overground walking speed assessment

  2. Timed Up and Go Test

    Time frame: 23 months

    Timed Up and Go Test overground walking assessment

  3. Berg Balance Scale

    Time frame: 23 months

    Berg Balance Scale for balance assessment

  4. Visual Analogue Scale

    Time frame: 23 months

    Visual Analogue Scale (VAS) for fear of falling assessment

  5. Spinal Cord Independence Measure (SCIM III)

    Time frame: 23 months

    Spinal Cord Independence Measure (SCIM III) for activity of daily living assessment

  6. World Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF)

    Time frame: 23 months

    World Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF) for quality of life assessment

Sponsors and collaborators

Lead sponsor

Ankara City Hospital Bilkent

Other

Registry information

Official study title

First Report of a New Exoskeleton in Incomplete Spinal Cord Injury: FreeGait®

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Nov 18, 2023
Registry last updated
Nov 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.